drugset / Trial / NCT05730699
Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to study the efficacy and safety of BCD-132 (divozilimab) in subjects with neuromyelitis optica spectrum disorders (NMOSD).
Timeline
- Start
- 2022-12-12
- Primary completion
- 2025-01
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Divozilimab | Monoclonal antibody | — | Intravenous |